eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
2/2021
vol. 38
 
Share:
Share:
abstract:
Original paper

Serum galectin-3 and galectin-3 binding protein levels in systemic lupus erythematosus and cutaneous lupus erythematosus

Agnieszka Kalinska-Bienias
1
,
Emilia Kowalczyk
1
,
Piotr Bienias
2
,
Kamila Gala
3
,
Pawel Jagielski
4
,
Cezary Kowalewski
1

1.
Department of Dermatology and Immunodermatology, Medical University of Warsaw, Warsaw, Poland
2.
Department of Internal Medicine and Cardiology, Medical University of Warsaw, Warsaw, Poland
3.
Department of Immunology, Transplantology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland
4.
Human Nutrition Department Faculty of Health Science, Jagiellonian University Medical College, Krakow, Poland
Adv Dermatol Allergol 2021; XXXVIII (2): 274-280
Online publish date: 2020/01/17
View full text Get citation
 
Introduction
The roles of galectin-3 (Gal-3) and galectin-3 binding protein (G3BP) in systemic lupus erythematosus (SLE) are of ongoing interest, but the data are insufficient due to highly limited available studies. There are no data on cutaneous lupus erythematosus (CLE).

Aim
To assess serum Gal-3 and G3BP concentrations in SLE patients with and without LE-specific skin lesions, CLE patients and to correlate levels of proteins with clinical and laboratory parameters.

Material and methods
The study included 71 SLE patients with and without LE-specific skin lesions, 23 CLE patients and 40 controls. Gal-3 and G3BP were measured by specific enzyme-linked immunosorbent assays (ELISA).

Results
Serum Gal-3 and G3BP concentrations were significantly higher in SLE with and without LE-specific lesions compared to controls, but without differences between SLE groups. Gal-3 and G3BP levels were also elevated in CLE compared to controls (p = 0.001, p = 0.005; respectively). There was a positive correlation between G3BP level and CLASI activity score both in CLE (r = 0.55, p = 0.006) and in SLE patients with LE-specific lesions (r = 0.36, p = 0.02). G3BP and Gal-3 levels did not differ in SLE with LE-specific lesions and CLE. There was a positive correlation between serum G3BP level and the SLEDAI score in SLE patients (r = 0.26, p = 0.03).

Conclusions
Our findings indicate that serum G3BP and Gal-3 are elevated in CLE. Additionally, G3BP might be associated with the extent of skin lesions. There are no differences between G3BP and Gal-3 concentrations in SLE with and without LE-specific skin lesions.

keywords:

galectin-3, galectin-3 binding protein, lupus erythematosus

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.